Hims & Hers Health将从2026年开始在加拿大提供仿制药semaglutide，因为专利到期。 Hims & Hers Health to offer generic semaglutide in Canada starting 2026 as patents expire.

《Hims & Hers Health》计划从2026年开始在加拿大提供普通微粒, 因为Ozempic和Wegovy等减重药品的专利到期。 Hims & Hers Health plans to offer generic semaglutide in Canada starting 2026, as patents on weight loss drugs like Ozempic and Wegovy expire. 该公司的股价在宣布扩大后上升了近6%。 扩大的目的是通过其数字平台提供负担得起的减肥解决方案,提供全天候获得保健提供者服务的机会。 The company's stock rose nearly 6% after announcing this expansion, which aims to provide affordable weight loss solutions through its digital platform, offering 24/7 access to healthcare providers. 到 2035 年，加拿大 semaglutide 市场预计将增长到 40.3 亿美元。 The Canadian semaglutide market is projected to grow to $4.03 billion by 2035.